Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04508426 · ClinicalTrials.gov registry record · Phase 1
Single-dose AME Study With [14C]AR882 in Healthy Male Subjects
A Phase 1 study of Healthy Volunteers, sponsored by Arthrosi Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT04508426 is a Phase 1 study of Healthy Volunteers that has completed, run by Arthrosi Therapeutics. The registered enrollment target is 6 participants, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04508426, a Phase 1 study of Healthy Volunteers, has completed, sponsored by Arthrosi Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label, single-dose, absorption, metabolism, excretion, and mass balance study following a single dose of \[14C\]AR882 in healthy adult male subjects. Whole blood, plasma, urine, and fecal samples will be analyzed for at least 144 hours following the single dose of AR882 to measure total radioactivity and plasma drug concentrations.
Conditions Studied
Interventions
- DRUG [14C]AR882
Study Locations (1)
Nebraska
- Celerion, Inc. - Lincoln
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2020-07-16 |
| Est. Completion | 2020-08-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04508426
The ClinicalTrials.gov registry entry for NCT04508426 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (99% lower). The listed sponsor is Arthrosi Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 1 intervention - of which [14C]AR882 is the first listed.
NCT04508426 reports 1 study location spanning 1 distinct geographic area - top geographies include Nebraska.
Frequently Asked Questions
What is clinical trial NCT04508426 about?
NCT04508426 is a clinical study titled "Single-dose AME Study With [14C]AR882 in Healthy Male Subjects". This is an open-label, single-dose, absorption, metabolism, excretion, and mass balance study following a single dose of \[14C\]AR882 in healthy adult male subjects. Whole blood, plasma, urine, and fecal samples will be analyzed for at least 144 hours following the single dose of AR882 to measure to...
What is the current status of trial NCT04508426?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2020-07-16. Estimated completion is 2020-08-12.
What conditions does trial NCT04508426 study?
This clinical trial studies the following conditions: Healthy Volunteers.
What interventions are being tested in trial NCT04508426?
The interventions under investigation include: [14C]AR882 (DRUG).
Who is sponsoring clinical trial NCT04508426?
This trial is sponsored by Arthrosi Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04508426 being conducted?
This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Volunteers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia
RECRUITING · Phase 1
-
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of ABBV-243 in Healthy Adults.
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of ABBV-277 in Healthy Adult Participants
RECRUITING · Phase 1
-
A Study to Evaluate the Effect of Single Oral Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participants.
RECRUITING · Phase 1
-
Classroom Break, Cognition, and Fitness in Elementary School Children
RECRUITING · Phase 1
-
A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult Participants
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.